By Fineline Cube 
Eisai Co., Ltd. (TYO: 4523) announced the commercial launch of a 14-tablet specification of its insomnia treatment Dayvigo (lemborexant) in China, complementing its previously approved 28-tablet package that received regulatory clearance in May 2025.
Product Launch Details
| Specification | Approval Status | Launch Date |
|---|---|---|
| 28-tablet package | Approved May 2025 | Previously launched |
| 14-tablet package | Commercial launch | April 2026 |
Multi-Channel Distribution Strategy
Major E-Commerce Platforms
- JD.com
- Alibaba
- Meituan
On-Demand Medication Platforms (O2O)
- JD Now
- Dingdang Kuaiyao O2O
Internet-Based Mental Health Platforms
- Zhaoyang Doctor
- Haoxinqing
This comprehensive distribution approach ensures patients can access Dayvigo through their preferred digital channels, from traditional e-commerce to specialized mental health platforms.
Market Rationale & Patient Benefits
- Addressing Evolving Demand: The 14-tablet specification responds to changing consumer preferences for more flexible sleep aid options
- Enhanced Convenience: Smaller pack size offers greater accessibility and reduced upfront cost barrier for new patients
- Scientific Sleep Support: Provides individuals with insomnia a clinically validated, convenient option backed by robust efficacy data
- Digital-First Accessibility: Aligns with China’s rapidly growing digital healthcare ecosystem and consumer preference for online medication purchasing
Strategic Significance
- Market Expansion: The dual-pack strategy (14-tablet + 28-tablet) enables Eisai to capture both trial users and established patients
- Digital Healthcare Integration: Positioning on mental health platforms demonstrates commitment to integrated care models
- Competitive Differentiation: Comprehensive multi-channel availability sets Dayvigo apart in China’s competitive insomnia treatment market
- Patient-Centric Approach: Flexible packaging options reflect Eisai’s focus on addressing real-world patient needs and barriers to treatment adherence
Forward‑Looking Statements
This brief contains forward-looking statements regarding Eisai’s commercial strategy, market positioning, and product availability. Actual sales performance and market penetration may vary based on competitive dynamics, reimbursement policies, and evolving consumer preferences.-Fineline Info & Tech